15 - New Antimicrobials in the Pipeline

Monday, October 20, 2025

8:00 AM - 9:00 AM US ET

Location: B302-B304

CME Credits: Maximum of 0 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0 hours of MOC Credit
CNE Credits: Maximum of 0 hours of ANCC Credit
ACPE Credits: ACPE 0 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 0 of PACE contact hours
CE Broker: Maximum of 0 CE broker credit hours

Moderator(s)

Lisa Dumkow, Pharm D., BCIDP (she/her/hers)

Antimicrobial Stewardship Clinical Pharmacist
Trinity Health Grand Rapids
Grand Rapids, MI, United States
David van Duin, MD, PhD

Professor of Medicine
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Disclosure(s):

Lisa E. Dumkow, Pharm D., BCIDP: No financial relationships to disclose.

David van Duin, MD, PhD: AbbVie Inc: Advisor/Consultant; Merck & Co., Inc.: Advisor/Consultant, Grant/Research Support; Parexel International: DSMB; Pfizer, Inc.: Advisor/Consultant, Honoraria; Roche Pharmaceuticals: Advisor/Consultant; TEVA: Advisor/Consultant

Presentations:

8:00 AM - 8:12 AM US ET

Nacubactam (OP0595): a Novel Triple-Action Diazabicyclooctane in Combination with Cefepime or Aztreonam
Industry Presenter: Hayato Okade, Ph.D – Meiji Seika Pharma Co., Ltd.
8:12 AM - 8:24 AM US ET

Clinical Validation and Mechanistic Understanding of Novel DNA pol IIIC Inhibitors to treat Gram-positive Bacterial Infections: Ibezapolstat advancing into global Phase 3 Clinical Trials for C. difficile Infection
Industry Presenter: Robert J. DeLuccia – Acurx Pharmaceuticals, Inc.
8:24 AM - 8:36 AM US ET

MRX-5 MicuRx Pharmaceuticals, Inc.
Industry Presenter: Regis A. Vilchez, MD,PhD – MicuRx Pharmaceuticals, Inc.
8:36 AM - 8:48 AM US ET

Developing bispecific monoclonal antibody (mAb) therapies, gremubamab and AZD0292, targeted against Pseudomonas aeruginosa sponsored by AstraZeneca
Industry Presenter: Tope Oyedele, MD (he/him/his) – AstraZeneca
8:48 AM - 9:00 AM US ET

Pritelivir, a nonnucleoside helicase-primase inhibitor, for the treatment of herpes simplex virus (HSV) infections in Phase 3 clinical development.
Industry Presenter: Alexander Birkmann, PhD (he/him/his) – AiCuris Anti-Infective Cures AG